Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

- PMLiVE

Amgen buys Danish partner Nuevolution for $167m

Copenhagen-based biotech will remain autonomous

- PMLiVE

As Europe goes to polls, pharma seeks to keep healthcare, R&D a priority

Eurosceptics want to block greater EU integration

- PMLiVE

No deal or revoke looming as fourth vote on Brexit nears

Voters set to protest via EU elections, no-deal remains possibility

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

Spinraza managed access deal in England breaks deadlock for Biogen

Patient groups remain wary, call for changes to NICE

- PMLiVE

Tax credit changes could put a ‘hard brake’ on UK biotech

Anti-fraud measures will hit genuine firms, fears BIA

- PMLiVE

Brexit “having impact on EU drug development”

EMA and UK regulator both affected

- PMLiVE

Novartis and Sanofi heads take on UK pharma leadership roles

Sector must fight for best Brexit outcome

- PMLiVE

England opens new NHS ‘front door’ to health innovators

An upgrade to existing ACC initiative

- PMLiVE

Brexit clock ticking once again, UK heads for European elections

New deadline gives pharma more time, but no more clarity

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

- PMLiVE

No-deal risk recedes, but new Brexit delay adds to uncertainty

Delay means industry must sustain no-deal investment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links